Key Highlights

  • Inovio Pharmaceuticals (NASDAQ:INO) traded at USD 1.7550 on November 2, 2026, about 191% above its USD 0.6024 close on October 30, after the FDA granted Voceryq Accelerated Approval that same day.
  • IDEXX Laboratories (NASDAQ:IDXX) jumped 19.92% to USD 661.00 from USD 551.21 after third-quarter Revenue of USD 1,214 million and 2026 EPS guidance lifted to USD 14.96 to USD 15.16, released before the open on November 2.
  • Perion Network Ltd (NASDAQ:PERI) climbed 31.03% to USD 11.40 after Affle 3i agreed on November 1, 2026 to pay USD 11.70 a share in cash, a 34.5% premium to the October 30 close of USD 8.70.
  • EVgo Inc. (NASDAQ:EVGO) surged 50.16% to USD 1.89 after a filing disclosed a USD 2.00 a share cash proposal from LS Power Equity Advisors. It is a proposal, not a signed agreement, and published coverage cites no board response.

1. Inovio Pharmaceuticals (NASDAQ:INO): An FDA Approval After a Sharp Fall

Inovio Pharmaceuticals (NASDAQ:INO) holds the clearest catalyst of the five. On Friday, October 30, 2026, the FDA announced accelerated approval of Voceryq, formerly INO-3107, the first plasmid DNA immunotherapy approved in the United States, for adults with recurrent respiratory papillomatosis. The shares had closed down 21.95% at USD 0.6024 that day, and the November 2 quote of USD 1.7550 is about 191% higher, simple arithmetic on two published numbers. Accelerated approval rests on fewer surgeries as an intermediate endpoint, so a confirmatory study is required and the approval can be withdrawn. Among 26 adults with at least three prior surgeries, 7 needed none in year one. Cash was USD 36.7 million at June 30, 2026, with a runway guided into late first quarter 2027, so another raise would dilute holders. Inovio Pharmaceuticals (NASDAQ:INO) also trades near USD 1, where spreads can be wide. The company expects shipments in about 60 days and full deployment in the first quarter of 2027.

2. Perion Network Ltd (NASDAQ:PERI): A Signed Cash Buyout

Perion Network Ltd (NASDAQ:PERI) announced a definitive Merger agreement on November 1, 2026 under which Affle 3i will pay USD 11.70 per share in cash, valuing the equity at about USD 420 million. The quote of USD 11.40 sits about 2.6% below the price, simple arithmetic, which reflects time to close, a Shareholder vote and the Hart-Scott-Rodino waiting period. A 40-day go-shop runs to December 11, 2026, letting the company solicit rival bids, and closing is expected in early 2027. The termination fee was not disclosed. The company held about USD 228.3 million of cash, deposits and marketable securities at September 30, 2026. Second-quarter revenue fell 5% to USD 98.2 million, so the standalone trend was softer. Perion Network Ltd (NASDAQ:PERI) is the lowest-risk story on this list if the deal closes. The board approved the agreement unanimously, and the deal has no financing condition, with Debt Financing from Citibank, N.A.

3. IDEXX Laboratories (NASDAQ:IDXX): Results and a Raised Outlook

IDEXX Laboratories (NASDAQ:IDXX) posted third-quarter 2026 results on Monday, November 2, before the open. Revenue came in at USD 1,214 million, up 10%, with diluted EPS of USD 4.01. Full-year revenue guidance was raised to USD 4.741 billion to USD 4.767 billion. That growth came even as U.S. same-store clinical visits fell an estimated 1.8%, which about 4% net price gains and 1,904 inVue Dx placements more than covered. At USD 661.00 the stock trades near 43.9 times the USD 15.06 guidance midpoint, simple arithmetic, so IDEXX Laboratories (NASDAQ:IDXX) is priced for steady execution. Consensus figures vary across summaries, so the size of the beat is approximate. IDEXX acquired CoVetAI on September 16 on undisclosed terms and expects to beat its 5,500 premium Placement goal for 2026.

4. TAT Technologies (NASDAQ:TATT): Record Quarter With Caveats

TAT Technologies (NASDAQ:TATT) reported record third-quarter results on November 2, the day it rose 15.38% to USD 36.69. Revenue was USD 55.6 million, up 20.2%, with a 30.9% gross Margin against 25.1% a year earlier. Net Income was USD 7.7 million, or USD 0.58 per diluted share, and adjusted EBITDA was USD 10.9 million. The quality of the print is mixed: Backlog and long-term agreements were about USD 577 million at September 30, below the USD 615 million cited at the second quarter, and Cash Flow weakened as inventory grew. No guidance was given. TAT Technologies (NASDAQ:TATT) closed at USD 32.68 on October 26 and still sits below its 52-week high of USD 64.50. Gross Profit was USD 17.2 million, and net income was up from USD 4.8 million a year earlier.

5. EVgo Inc. (NASDAQ:EVGO): A Proposal From a Major Holder

EVgo Inc. (NASDAQ:EVGO) disclosed on November 2, 2026 that LS Power Equity Advisors proposed buying it for USD 2.00 a share in cash, per a regulatory filing. That offer sits about 59% above the USD 1.26 prior close, and the USD 1.89 quote is about 5.5% below it, simple arithmetic. Published coverage puts LS Power at about 178 million shares, roughly 56% of voting securities, from a single source. No board response or definitive agreement had been reported, and a proposal from a large holder is not binding. EVgo Inc. (NASDAQ:EVGO) reports third-quarter results on November 9 at 9:00 a.m. ET, following second-quarter revenue of USD 82.6 million, down 16%. Per published coverage, UBS cut its target to USD 2.00 and RBC Capital to USD 1.75.

Where Things Stand

The top five confirmed catalysts are an FDA approval, a signed buyout, a raised outlook, record results and a controlling-holder proposal, and they differ widely in certainty. Inovio Pharmaceuticals (NASDAQ:INO) still faces dilution and confirmatory trial risk. Perion Network Ltd (NASDAQ:PERI) has the firmest terms, with a go-shop to December 11. IDEXX Laboratories (NASDAQ:IDXX) carries a premium multiple. TAT Technologies (NASDAQ:TATT) lacks guidance, and EVgo Inc. (NASDAQ:EVGO) awaits a board response. Intraday moves can change by the close. The next checkpoints are first shipments in about 60 days, the go-shop result, the November 9 webcast and any board statement.